Affiliation:
1. Chazov National Medical Research Center of Cardiology
2. Servier company
Abstract
Aim. To describe antihypertensive effectiveness of triple fixed-dose combination of am lo dipine/indapamide/perindopril and assess predictors of its clinical effectiveness in pati ents depending on body mass index (BMI) and presence of type 2 diabetes (T2D).Material and methods. This observational prospective study TRICOLOR (NCT03722524) (n=1247) demonstrated high antihypertensive effectiveness and good tolerability of amlodipine/indapamide/perindopril fixed-dose combination. Subgroup analyzes based on BMI included data from 1144 patients. In a second subgroup analysis, 1128 patients were stratified according to concomitant T2D.Results. In patients with overweight/obesity and diabetes, good antihypertensive effectiveness of amlodipine/indapamide/perindopril was observed, comparable in blood pressure (BP) reduction with the comparison groups (patients with normal BMI and patients without diabetes). At the same time, patients with normal BMI, compared with patients with overweight and obesity, had significantly lower systolic BP (SBP) (after 4 and 12 weeks) and diastolic BP (DBP) (after 2 and 12 weeks). In the subgroups, depending on the diabetes status, there were no significant differences in the decrease in SBP and DBP levels at all follow-up points. By the 12th week, BP decrease in the group of patients with normal BMI was 32,9 (10,5)/15,3 (8,6) mm Hg, in the group with overweight — 33,2 (11,3)/14,2 (8,5) mm Hg, in the obesity group — 33,9 (12,3)/14,1 (8,8) mm Hg (p>0,05 for intergroup comparison). Target BP <140/90 mm Hg already after 2 weeks of therapy achieved a higher number of patients with a normal BMI compared to overweight group (50,8% vs 37,2%, p=0,009). By the 12th week, the vast majority of patients, regardless of BMI and diabetes status, achieved a target BP <140/90 mm Hg, which demonstrates a good and rapid response to triple fixed-dose therapy.Conclusion. Thus, additional analyzes of the TRICOLOR study demonstrate the high antihypertensive effectiveness of amlodipine/indapamide/perindopril in hypertensive patients, regardless of the presence of diabetes, overweight or obesity.
Reference41 articles.
1. NCD Risk Factor Collaboration (NCDRisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population representative studies with 104 million participants. Lancet. 2021; 398(10304):95780. doi:10.1016/S01406736(21)013301. Erratm in: Lancet. 2022; 399(10324):520.
2. Balanova YuA, Drapkina OM, Kutsenko VA, et al. Hypertension in the Russian population during the COVID19 pandemic: sex differences in prevalence, treatment and its effectiveness. Data from the ESSERF3 study. Cardiovascular Therapy and Prevention. 2023;22(8S):3785. (In Russ.) doi:10.15829/1728880020233785.
3. Tanaka M, Itoh H. Hypertension as a Metabolic Disorder and the Novel Role of the Gut. Curr Hypertens Rep. 2019;21(8):63. doi:10.1007/s1190601909645.
4. Balanova YuA, Drapkina OM, Kutsenko VA, et al. Obesity in the Russian population during the COVID19 pandemic and associated factors. Data from the ESSERF3 study. Cardiovascular Therapy and Prevention. 2023;22(8S):3793. (In Russ.) doi:10.15829/1728880020233793.
5. Harsha DW, Bray GA. Weight Loss and Blood Pressure Control (Pro). Hypertension. 2008;51:14205. doi:10.1161/HYPERTENSIONAHA.107.09411.